Release Details

SOUTH PLAINFIELD, N.J., April 23, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:

• Deutsche Bank 40th Annual Health Care Conference, on Wednesday, May 6^th  at 10 a.m. ET at The InterContinental Hotel in Boston, MA
• Bank of America Merrill Lynch, 2015 Health Care Conference, on Tuesday, May 12^th at 10 a.m. PT at the Encore at Wynn in Las Vegas, NV

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation and R&D Day slides are available at the same website location.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-300070882.html

SOURCE PTC Therapeutics, Inc.